Biotech | August 20, 2021
Enzene Biosciences obtains DCGI approval for Romiplostim biosimilar
It is the only biopharmaceutical company in India to offer all three dosage strengths of the drug (125mcg, 250mcg, and 500mcg)
It is the only biopharmaceutical company in India to offer all three dosage strengths of the drug (125mcg, 250mcg, and 500mcg)
Idiopathic hypersomnia is a life-long condition, and the approval of Xywav will be instrumental in providing treatment for symptoms such as excessive sleepiness and difficulty waking, and in effectively managing this debilitating disorder
It leverages Kite’s Chimeric Antigen Receptors and Appia Bio’s Allogeneic Cell Technology Platform to Develop Off-the-Shelf Cell Therapies
Besides powering the drug discovery efforts, phytopharmaceuticals have a huge potential to create a niche market for itself, thereby helping to expand the bio-economy.
posaconazole delayed-release tablets 100 mg are the generic equivalent of Noxafil.
The DREAM-ND Phase III trial has now enrolled 588 CKD patients not-on-dialysis.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)